Quote:

---

Just, when you say, "it causes HIV viral reservoirs", what is "it"?

---

The it is the other viral infection and would most likely be caused by the downstream effects in the rise of cytokines and other CCR5 receptors.

One intriguing thing is that maraviroc causes the the viral reservoirs to release and deplete. Almost certainly leronlimab does the same. I haven't seen it mentioned anywhere but it's possible that viral reservoirs trigger when there is a lack of active HIV.

Quote:

---

Ohm, please, I'm not imposing and if you are too busy or strapped, I completely understand, and time is of no concern to me, but if you are nudged, then, I was hoping you wouldn't mind describing in general terms how the normal, CD4 count, CD8 count & the CD4/CD8 ratio are generally affected by the development of HIV infection and then even worse, as it progresses into full blown AIDS.

---

Going from HIV to AIDS is straightforward. HIV actively destroys CD4/CCR5 cells when replicating and the destruction of CD4 cells negatively affects the creation of CD8 cells and their differentiation. This results in the annihilation of the immune system. Then opportunistic infections and diseases take over and results in AIDS.

What we're looking at in the upcoming trial is HIV controlled by ART. The variation in CD4/CD8 count is what you find in ART controlled HIV.

Quote:

---

Also, how does the addition of ART affect those same cell counts and ratio in both the progression of HIV and then into full blown AIDS, so as to observe varying counts among the cell types within these stages.

---

ART controls the HIV infection so there is no progression to AIDS unless you have failing ART due to drug resistance. The ratio of CD4/CD8 you could say was balanced since both are at extremely low levels.

One thing that I'm sure the FDA hasn't considered by Dr. Lalezari has is that leronlimab as a treatment for HIV immune dysfunction would also be ideal for HIV itself if we can figure out how to get rid of the blips. If those blips occur only in early usage of leronlimab but not later a combo treatment at first followed by monotherapy may be possible.